Albireo Pharma Inc
F:BDQM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Albireo Pharma Inc
F:BDQM
|
US |
|
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
|
CN |
|
Jhaveri Credits and Capital Ltd
BSE:531550
|
IN |
|
ME Group International PLC
LSE:MEGP
|
UK |
|
Aquis Exchange PLC
LSE:AQX
|
UK |
|
TPG Telecom Ltd
ASX:TPG
|
AU |
|
N
|
Nyocor Co Ltd
SSE:600821
|
CN |
|
N
|
Nahar Capital and Financial Services Ltd
NSE:NAHARCAP
|
IN |
|
C
|
Cheuk Nang Holdings Ltd
HKEX:131
|
HK |
|
Vienna Insurance Group AG Wiener Versicherung Gruppe
OTC:VNRGF
|
AT |
|
Central Garden & Pet Co
NASDAQ:CENT
|
US |
|
Feintool International Holding AG
SIX:FTON
|
CH |
|
P
|
Prakash Pipes Ltd
BSE:542684
|
IN |
|
Global Arena Holding Inc
OTC:GAHC
|
US |
|
Aydem Yenilenebilir Enerji AS
IST:AYDEM.E
|
TR |
|
F
|
Fincera Inc
OTC:YUANF
|
US |
|
V
|
VIMAB Group AB (publ)
STO:VIMAB
|
SE |
|
Cyanconnode Holdings PLC
LSE:CYAN
|
UK |
|
S
|
Shanghai Model Organisms Center Inc
SSE:688265
|
CN |
|
N
|
Nichicon Corp
TSE:6996
|
JP |
|
Asaka Riken Co Ltd
TSE:5724
|
JP |
|
Delta Resources Ltd
XTSX:DLTA
|
CA |
|
Bigtincan Holdings Ltd
ASX:BTH
|
AU |
|
Mid-Southern Bancorp Inc
OTC:MSVB
|
US |
Albireo Pharma Inc
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
